Full Text Here

Interested party (Organisations or individuals) that commented on the draft Guideline as released for
consultation
Stakeholder
No.
Name of Organisation or individual
1 OARSI, Osteoarthritis Research Society International
2 USZ, Department of Rheumatology and Institute of Physical Medicine, University Hospital
of Zurich, Switzerland
3 AESGP, Association of the European Self-Medication Industry
4 EFPIA
5 GREES, Osteoarthritis section
6 EULAR
Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulattions, rules and initiatives each month, and summarise them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

The concept paper starts by outlining the classification of anti-osteoarthritis therapies, these are medications that affect the symptoms and/or modify structures within the disease. The nomenclature currently proposed recognises 3 types of drugs acting on osteoarthritis: fast acting drugs that induce symptomatic relief, slow acting drugs that induce symptomatic relief and disease modifying drugs.

Due to the pathophysiological differences of osteoarthritis in different body parts the EMEA treats different body parts sa different indications for the purposes of results interpretation and product registration.

The paper also goes on to describe the primary and secondary efficacy endpoints for the different types of drug: symptom modifying drugs, largely rely on pain and function as primary endpoints. Structure modifying drugs rely on long-term outcomes such as necessity for joint replacement time to need surgery and long-term clinical performance (pain and disability).

The paper also includes guidance on clinical trial design for dose finding and therapeutic comparative trials: study population is given particular attention, as is concomitant interventions. The use of placebo and the choice of comparators is also addressed in the document as are safety considerations.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug  development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

As you know this website is a great resourse for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.